Yves Fradet
Affiliations: | Universite Laval (Canada) |
Area:
Biochemistry, OncologyGoogle:
"Yves Fradet"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Besançon M, Gris T, Joncas FH, et al. (2022) Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment. European Urology Open Science. 43: 35-44 |
| Plante A, Dallaire F, Grosset AA, et al. (2021) Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimens. Journal of Biomedical Optics. 26 |
| Powles T, van der Heijden MS, Castellano D, et al. (2020) Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. The Lancet. Oncology |
| Grosset AA, Dallaire F, Nguyen T, et al. (2020) Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation. Plos Medicine. 17: e1003281 |
| Toren P, Brisson H, Simonyan D, et al. (2020) Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival. World Journal of Urology |
| Lévesque E, Labriet A, Hovington H, et al. (2020) Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression. British Journal of Cancer |
| Leong DP, Fradet V, Shayegan B, et al. (2020) Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study. The Journal of Urology. 101097JU000000000000 |
| Pinthus JH, Shayegan B, Klotz L, et al. (2020) The prevalence of cardiovascular disease and its risk factors among prostate cancer patients treated with and without androgen deprivation. Journal of Clinical Oncology. 38: 364-364 |
| Pinthus* J, Shayegan B, Siemens R, et al. (2020) PD13-10 THE PREVALENCE OF CARDIOVASCULAR DISEASE AND ITS RISK FACTORS AMONG PROSTATE CANCER PATIENTS TREATED WITH AND WITHOUT ANDROGEN DEPRIVATION The Journal of Urology. 203: e270 |
| McMartin C, Lacombe L, Fradet V, et al. (2019) Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive? Clinical Genitourinary Cancer |